Loud and clear: Australian start-ups changing the hearing game
25 March 2019 For Dr Kate Lomas and Dr Liz Williams, understanding insect ears is the key to unlocking a billion-dollar industry. “We really see this as a dramatically improved treatment for profoundly deaf patients, and we’re aiming…
Johnson & Johnson joins forces with Monash University-led partnership to advance novel technology aimed at saving lives of women in child birth
21 March 2019 | The biggest cause of pregnancy-related death in resource-limited settings is excessive blood loss after birth, a condition effectively managed in developed countries with injectable oxytocin administered by trained personnel. A novel form of oxytocin,…
GSK puts Australian researchers on Discovery Fast Track
GSK will provide access to its expertise in research, platform technologies and compounds to researchers from Monash University and the University of South Australia. Collaboration between academia and industry through joint research teams to help accelerate discovery of…
Australia is handicapped in the delivery of cell therapies, says Alan Trounson
20 March 2019 THE promise is remarkable: a new class of affordable, effective cancer treatments beyond surgery, chemotherapy, biologicals and radiation. Imagine cancer specialists being able to select from a range of treatments to supercharge a patient’s immune…
Austin Health ID to join the Doherty Institute
18 March 2019 | Announcement from Professor Sharon Lewin, Director, Doherty Insititute: I am thrilled to announce that Austin Health’s Infectious Diseases Department (Austin Health ID) is joining the Peter Doherty Institute for Infection and Immunity (Doherty Institute)…
The Global Health Alliance Welcomes Labor’s Pacific Avoidable Blindness and Vision Loss Fund
14 March 2018 The Senator Hon Penny Wong announced that if elected, a Labor Government will invest $32 million in a Pacific Avoidable Blindness and Vision Loss Fund. “At a time when Australia’s focus is returning to the…
Media release: Victorian medtech startups to get strategy boost for entering the US healthcare market
14 March 2019 | A new program to help Victorian medtech startups enter the US market is being launched next week in Melbourne. Healthtech Reimbursement: Getting Paid in the USA has been developed by BioMelbourne Network, with support…
New space for Outerspace Melbourne
8 March 2019 | Outerspace Melbourne has settled in the new makerspace in Abbotsford, a short drive from the old studio. The team enjoyed designing the “clean slate” space and making it their own, with an open layout…
Immutep presents positive IMP761 preclinical results
8 March 2019 | Immutep today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European…
Immutep doses first patient in TACTI-002 Phase II trial
8 March 2019 | Immutep has just announced that the first patient has been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of their lead product candidate, eftilagimod alpha (“efti”), and KEYTRUDA®…
Immutep announces data from ongoing TACTI-mel Phase I clinical trial in unresectable or metastatic melanoma
8 March 2019 | This week at the World Immunotherapy Congress 2019 in San Diego USA, Immutep announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the company’s lead product candidate, eftilagimod alpha…
Mayne Pharma treatment for chronic breathlessness approved by TGA
20 February 2019 | Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the Therapeutic Goods Administration (TGA) has approved KAPANOL® low dose sustained-release 10mg and 20mg morphine capsules for the treatment of chronic breathlessness in…
